BRIEF-Puma Biotechnology And Pierre Fabre Amend Nerlynx License Agreement
BRIEF-Puma Biotechnology And Pierre Fabre Amend Nerlynx License Agreement
* PUMA BIOTECHNOLOGY AND PIERRE FABRE AMEND NERLYNX® LICENSE AGREEMENT TO INCLUDE GREATER CHINA
* PUMA BIOTECHNOLOGY INC - CO, CANBRIDGE PHARMACEUTICALS TERMINATE LICENSE AGREEMENT IN GREATER CHINA
* PUMA BIOTECHNOLOGY INC - UNDER TERMS, CO WILL RECEIVE AN UPFRONT PAYMENT OF $50 MILLION
* PUMA BIOTECHNOLOGY - UNDER TERMS, CO WILL RECEIVE AN ADDITIONAL REGULATORY, SALES-BASED MILESTONE PAYMENTS THAT COULD ADD UP TO AN ADDITIONAL $240 MILLION
* PUMA BIOTECHNOLOGY INC - IN ADDITION, PUMA WILL RECEIVE SIGNIFICANT DOUBLE-DIGIT TIERED ROYALTIES ON SALES OF NERLYNX IN GREATER CHINA
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;)
Feb 25 (Reuters) - Puma Biotechnology Inc :
* PUMA BIOTECHNOLOGY AND PIERRE FABRE AMEND NERLYNX® LICENSE AGREEMENT TO INCLUDE GREATER CHINA
* PUMA BIOTECHNOLOGY INC - CO, CANBRIDGE PHARMACEUTICALS TERMINATE LICENSE AGREEMENT IN GREATER CHINA
* PUMA BIOTECHNOLOGY INC - UNDER TERMS, CO WILL RECEIVE AN UPFRONT PAYMENT OF $50 MILLION
* PUMA BIOTECHNOLOGY - UNDER TERMS, CO WILL RECEIVE AN ADDITIONAL REGULATORY, SALES-BASED MILESTONE PAYMENTS THAT COULD ADD UP TO AN ADDITIONAL $240 MILLION
* PUMA BIOTECHNOLOGY INC - IN ADDITION, PUMA WILL RECEIVE SIGNIFICANT DOUBLE-DIGIT TIERED ROYALTIES ON SALES OF NERLYNX IN GREATER CHINA
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;)
路透2月25日電-彪馬生物技術公司(Puma Biotechnology Inc)：*PUMA生物技術和Pierre Fabre修改NERLYNX®許可協議，將大中華區包括在內*PUMA生物技術公司-CO，Canbridge製藥公司在大中華區終止許可協議*PUMA生物技術公司-根據條款，CO將收到5000萬美元的預付款*PUMA生物技術-根據條款，CO將獲得額外的監管、基於銷售的里程碑付款，總計可能額外獲得2.4億美元*PUMA生物技術公司-此外，PUMA將從NERLYNX在大中華區的銷售中獲得可觀的兩位數分級特許權使用費Eikon的源文本：進一步的公司報道：(Reurs.Briefs@thomsonreurs.com；)
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧